The study on the serum levels of novel adipokines in children with central precocious puberty

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2600128354

Enrollment

Unknown

Registered

2026-07-17

Start date

2024-11-28

Completion date

Unknown

Last updated

2026-07-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Central Precocious Puberty (CPP): A common pediatric endocrine disorder caused by the premature activation of the hypothalamic-pituitary-gonadal (HPG) axis, leading to rapid development of internal and external reproductive organs and the appearance of secondary sexual characteristics before the age of 7.5 years in girls and 9 years in boys.Isolated Premature Thelarche: The development of breast t

Interventions

Healthy Control:None

Central precocious puberty:None

Eligibility

Sex/Gender

All

Age

3 Years to 14 Years

Inclusion criteria

Inclusion criteria: 1. Informed consent form with signature and date 2. Commit to comply with the research procedures and cooperate throughout the entire research process 3. Children aged 3–14 years 4. Children with central precocious puberty who meet the diagnostic criteria of the 2022 consensus on diagnosis and treatment of central precocious puberty, and normal children

Exclusion criteria

Exclusion criteria: 1.Other cases of precocious puberty that do not meet the diagnostic criteria for central precocious puberty as defined in the 2022 consensus on diagnosis and treatment of precocious puberty; 2.those whose blood sample is not collected within 6:00 - 8:00 am. 3.Excluding children with precocious puberty, obesity, anorexia nervosa, those who have taken weight-loss medications or estrogen drugs, those who have taken medications for thyroid diseases, those with a history of related surgeries for weight loss, those with a history of tumor radiotherapy and chemotherapy, those with autism, sleep disorders, juvenile idiopathic arthritis, those who have undergone anesthesia and surgery, etc.

Design outcomes

Primary

Measure	Time frame
Novel adipokines (Kisspeptin, Chemerin, Resistin, Visfatin, Apelin, Leptin, Adiponectin);	—

Countries

China

Contacts

Public ContactNing Xin

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

ningxin0821@163.com+86 27 84289562

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jul 23, 2026